Praesidia Bio – Solving Problems that Matter

Treating CNS Disorders Today

Millions suffer without sufficient treatment.

CNS disorders cause more years of ill health than either cardiovascular disease or cancer. Schizophrenia, Epilepsy, Alzheimer’s Disease, and Depression are not adequately addressed by current medicines. They affect the day-to-day lives of millions of patients and their families – 3.5m Schizophrenia patients in the US alone.

While many scientific and medical advances have eased unimaginable suffering for patients and their families, these advances trail other areas of medicine. An alarming increase in burden is expected to grow as our population ages.

‍

Efficacy is capped by tolerability.

Many existing CNS medicines, including those of muscarinic variety, carry significant burdens: intolerable gastrointestinal issues, multiple dosing regimens, and other truly life-impeding side effects. These issues often limit patients' and health providers' ability to deliver enough efficacious medicine to the brain, leaving many patients unable or unwilling to take the correct dose for their condition.

This tolerability limit leaves existing patients underserved and the healthcare system unprepared for the coming aging-driven rise in CNS conditions.

Unrealized biological potential.

Muscarinic biology has long been recognized as crucial for the treatment of many diseases, especially for the brain.

Recent advances demonstrate the potential of muscarinic agents to deliver better clinical outcomes relative to existing CNS treatments, focusing on novel neurotransmission targets and improving the cognitive ability of patients across CNS disorders.

Enabling muscarinic agents that are highly efficacious and can be tolerated is a ‘holy grail’ for neuropsychiatric treatment.

Our Approach is Simple

Focusing on the right problems, for the right conditions, in the right patients.

Praesidia is optimizing selectivity, potency, and kinetics of existing and novel muscarinic agents to accelerate their use for the treatment of CNS disorders.

We want each patient to reach the dose necessary to treat their condition – without efficacy being capped by tolerability. We believe this approach will deliver superior results to patients relative to current in-market therapies.

Our compounds are engineered to improve CNS selectivity, target binding, and blood kinetics. We expect that this approach will reduce side effects and simplify dosing for better adherence.
‍

our Science

Our Experienced Team

Bringing together the right people to solve the right problem is the first step to success. The Praesidia team is united by a shared commitment to solve hard problems that matter. The outcome we hope for is dramatically improved treatments for CNS disorders. Our experienced Team bring together drug development expertise across chemistry, biology, pharmacology, and neuroscience.

Meet Our Team